Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL1766280 | 1.00 | LMNA (0.36) | — | |
| Metformin SCHEMBL1333960 | 0.97 | LMNA (0.35) | — | |
| Metformin SCHEMBL22127017 | 0.97 | LMNA (0.35) | — | |
| Metformin SCHEMBL18953625 | 0.97 | HTT (0.39) | — | |
| Metformin SCHEMBL4421557 | 0.97 | HTT (0.39) | — | |
| Metformin SCHEMBL433864 | 0.97 | HTT (0.39) | — | |
| Metformin SCHEMBL1290484 | 0.97 | LMNA (0.35) | — | |
| Metformin SCHEMBL1560020 | 0.97 | LMNA (0.35) | — | |
| Metformin SCHEMBL15268394 | 0.97 | HTT (0.39) | — | |
| Metformin SCHEMBL292820 | 0.97 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 101262 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | POLYAMYNA NANOTECH INC. (CA) | 2026-05-28 | — | — | US | claimed |
| EP-4747279-A1 | METHOD FOR BOOSTING THE EFFICACY OF IMMUNOTHERAPY AND ENHANCING THE HOST IMMUNE RESPONSE | Andremacon S.r.l. (IT) | 2026-05-27 | — | — | EP | claimed |
| EP-4748438-A2 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | Cedars-Sinai Medical Center (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075465-A | Use of propionyl carnitine for improving obesity and insulin resistance | — | 2026-05-26 | — | — | CN | claimed |
| CN-121202992-B | Novel long-acting Amylin receptor agonist and application thereof | Hangzhou Nuo Ao Biopharmaceutical Technology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122075608-A | Preparation method of metformin compound hypoglycemic oral liquid | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079768-A | Method for selectively and efficiently depolymerizing and recycling PET in waste blended fabric | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075699-A | Application of calcium activated chloride channel AN01/TMEM16A in preventing and treating atherosclerosis | — | 2026-05-26 | — | — | CN | claimed |
| CN-122091220-A | Pregnancy individual blood concentration prediction factor screening method, prediction model construction method and prediction system | — | 2026-05-26 | — | — | CN | claimed |
| CN-122091237-A | System, method and application for predicting after-same-room live birth of polycystic ovary syndrome patient with ovulation induction guidance | — | 2026-05-26 | — | — | CN | claimed |
| EP-0458949-A1 | STABILIZATION OF K1K2P PRO. | BOEHRINGER MANNHEIM GMBH (DE) | 1991-12-04 | — | — | EP | claimed |
| WO-1991012003-A1 | USE OF INSULIN SENSITIZING AGENTS TO TREAT HYPERTENSION | THE UPJOHN COMPANY (US) | 1991-08-22 | — | — | WO | claimed |
| WO-1991008767-A1 | STABILIZATION OF GLYCOSYLIZED t-PA | BOEHRINGER MANNHEIM GMBH (DE) | 1991-06-27 | — | — | WO | claimed |
| WO-1991008766-A1 | STABILIZATION OF t-PA pro | BOEHRINGER MANNHEIM GMBH (DE) | 1991-06-27 | — | — | WO | claimed |
| WO-1991008763-A1 | STABILIZATION OF K1K2P PRO | BOEHRINGER MANNHEIM GMBH (DE) | 1991-06-27 | — | — | WO | claimed |
| WO-1991008765-A1 | STABILIZATION OF K2P PRO | BOEHRINGER MANNHEIM GMBH (DE) | 1991-06-27 | — | — | WO | claimed |
| US-4835184-A | Novel pharmaceutical compositions intended to the treatment of neuropathies and promoting the nervous regeneration | ALBERT ROLLAND SA (FR) | 1989-05-30 | — | — | US | claimed |
| EP-0283369-A2 | Use of Metformin in the preparation of medicaments | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1988-09-21 | — | — | EP | claimed |
| EP-0214017-A2 | Use of N,N,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1987-03-11 | — | — | EP | claimed |
| US-4080472-A | TREATMENT OF GLYCAEMIA AND/OR CHOLESTEROLAEMIA | SOCIETE D'ETUDES ET D'EXPLOITATION DE MARQUES ET BREVETS S.E.M.S. (FR) | 1978-03-21 | — | — | US | claimed |